#United States #New York #Class Action #Levi & Korsinsky #Regeneron

Important Update for Regeneron Pharmaceuticals Investors

In a recent announcement, Levi & Korsinsky, LLP has brought to the attention of investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that the firm has filed a class action lawsuit concerning the company. This timely notice serves to inform shareholders regarding vital deadlines and the details surrounding the allegations made against the company.

Overview of the Lawsuit

The class action lawsuit is centered on accusations of securities fraud occurring between November 2, 2023, and October 30, 2024. The lead plaintiff deadline for shareholders to participate in this lawsuit is set for March 10, 2025. This means that if you were an investor during this period and believe you have suffered financial losses due to deceptive practices, you must act quickly to express your interest in joining the lawsuit.

Allegations Against Regeneron

The lawsuit challenges several aspects of Regeneron’s business operations, specifically focusing on alleged misleading statements made by the company. Key points of concern include claims that Regeneron engaged in practices that led to artificially inflated sales figures for Eylea, one of its primary products. The allegations specify that:
1. Regeneron allegedly paid credit card fees to distributors under conditions that prevented them from passing these charges on to Eylea customers.
2. These payments reportedly helped subsidize the prices customers faced when purchasing Eylea with credit cards.
3. Consequently, Regeneron purportedly offered price concessions that lowered the selling price of Eylea, subsequently misleading shareholders about the company’s sales performance.
4. The firm is accused of failing to accurately report credit card fee payments as part of the pricing structure.
5. This misleading information resulted in a violation of the False Claims Act, as it exaggerated the Average Selling Price (ASP) of Eylea reported to federal agencies.

These allegations could have significant implications for Regeneron's reputation and financial standing, as the lawsuit suggests that the defendants' prior statements lacked a reasonable basis and were materially misleading.

Next Steps for Affected Investors

If you are a shareholder of Regeneron Pharmaceuticals and believe you were impacted during the specified timeframe, it is critical to understand your rights. The firm encourages you to come forward by the March 10, 2025 deadline and consider requesting the Court to appoint you as a lead plaintiff. It’s important to emphasize that participation in the lawsuit does not require you to serve as a lead plaintiff, and there are no upfront costs for class members.

Levi & Korsinsky has a strong track record of supporting investors in securities litigation, having successfully recovered hundreds of millions of dollars for shareholders over the past two decades. Their experienced team, comprised of over 70 professionals, is dedicated to advocating for the rights of aggrieved investors, making them a reputable choice for representation in this significant lawsuit.

Contact Information

For more information about the class action or if you wish to discuss your situation with a legal representative, you can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky:

• - Email: [email protected]
• - Phone: (212) 363-7500

Regeneron Pharmaceuticals continues to be a prominent name within the pharmaceutical sector. However, it is essential for stakeholders to stay informed about the developments arising from this lawsuit, which may affect the company’s operations and stock performance in the future. As the deadline approaches, affected investors are urged to explore their options to ensure their interests are protected in the unfolding legal scenarios concerning Regeneron Pharmaceuticals.